The effect of apatinib on pharmacokinetic profile of buspirone bothin vivoandin vitro

被引:5
作者
Zhang, Xiao-dan [1 ]
Li, Ying-hui [2 ]
Chen, Dao-xing [2 ]
You, Wei-wei [2 ]
Hu, Xiao-xia [3 ,4 ]
Chen, Bing-bing [2 ]
Hu, Guo-xin [2 ]
Qian, Jian-chang [2 ]
机构
[1] Seventh Peoples Hosp Wenzhou, Wenzhou, Zhejiang, Peoples R China
[2] Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou 325000, Zhejiang, Peoples R China
[3] Zhejiang Univ, Jinhua Hosp, Jinhua, Zhejiang, Peoples R China
[4] Jinhua Municipal Cent Hosp, Jinhua, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
apatinib; buspirone; drug interaction; metabolism; pharmacokinetics; ACTIVE METABOLITE;
D O I
10.1111/jphp.13320
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective In this study, we aimed to investigate the potential interaction of apatinib and buspirone and underlying mechanism. Methods UPLC-MS/MS assay was applied to determine the concentrations of buspirone and its main metabolites (1-PP and 6-OH buspirone) after incubated with liver microsomes. Moreover, the connection ofin vitroandin vivowas further determined. Sprague Dawley rats were randomly divided into two groups: group A (20 mg/kg buspirone) and group B (buspirone vs 40 mg/kg apatinib). Tail vein blood was collected and subjected to the UPLC-MS/MS detection. Key findings Apatinib inhibited the generations of 1-PP and 6-OH buspirone dose-dependently with IC(50)of 1.76 and 2.23 mu min RLMs, and 1.51 and 1.48 mu min HLMs,respectively. There was a mixed mechanism underlying such an inhibition effect. In rat, AUC((0-)(t)()), AUC((0-infinity)),T(max)andC(max)of buspirone and 6-OH buspirone increased significantly while co-administering with apatinib, butV(z/F)and CL(z/F)decreased obviously while comparing group A with group B . Conclusions Apatinib suppresses the CYP450 based metabolism of buspirone in a mixed mechanism and boosted the blood exposure of prototype drug and 6-OH buspirone dramatically. Therefore, extra caution should be taken when combining apatinib with buspirone in clinic.
引用
收藏
页码:1405 / 1411
页数:7
相关论文
共 26 条
  • [1] Buspirone: Future directions
    Apter, JT
    Allen, LA
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (01) : 86 - 93
  • [2] Evaluation of the inhibition effects of apatinib on human and rat cytochrome P450
    Bao, Su-su
    Wen, Jian
    Zheng, Xiang
    Zhou, Quan
    Qu, Gao-er
    Chen, Ming-jing
    Hu, Guo-xin
    [J]. TOXICOLOGY LETTERS, 2018, 297 : 1 - 7
  • [3] Is there a role for 5-HT1A agonists in the treatment of depression?
    Blier, P
    Ward, NM
    [J]. BIOLOGICAL PSYCHIATRY, 2003, 53 (03) : 193 - 203
  • [4] Latent class analysis differentiation of adjustment disorder and demoralization, more severe depressive and anxiety disorders, and somatic symptoms in patients with cancer
    Bobevski, I.
    Kissane, D. W.
    Vehling, S.
    McKenzie, D. P.
    Glaesmer, H.
    Mehnert, A.
    [J]. PSYCHO-ONCOLOGY, 2018, 27 (11) : 2623 - 2630
  • [5] Metabolism and Pharmacokinetics of Novel Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor Apatinib in Humans
    Ding, Juefang
    Chen, Xiaoyan
    Gao, Zhiwei
    Dai, Xiaojian
    Li, Liang
    Xie, Cen
    Jiang, Haoyuan
    Zhang, Lijia
    Zhong, Dafang
    [J]. DRUG METABOLISM AND DISPOSITION, 2013, 41 (06) : 1195 - 1210
  • [6] Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range
    Dockens, Randy C.
    Salazar, Daniel E.
    Fulmor, J. Edgar
    Wehling, Michele
    Arnold, Mark E.
    Croop, Robert
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (11) : 1308 - 1312
  • [7] BUSPIRONE - REVIEW OF ITS PHARMACOLOGY AND CURRENT PERSPECTIVES ON ITS MECHANISM OF ACTION
    EISON, AS
    TEMPLE, DL
    [J]. AMERICAN JOURNAL OF MEDICINE, 1986, 80 (3B) : 1 - 9
  • [8] The safety of apatinib for the treatment of gastric cancer
    Geng, Ruixuan
    Song, Li
    Li, Jin
    Zhao, Lin
    [J]. EXPERT OPINION ON DRUG SAFETY, 2018, 17 (11) : 1145 - 1150
  • [9] BUSPIRONE - A PRELIMINARY REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC EFFICACY AS AN ANXIOLYTIC
    GOA, KL
    WARD, A
    [J]. DRUGS, 1986, 32 (02) : 114 - 129
  • [10] Buspirone, fexofenadine, and omeprazole: Quantification of probe drugs and their metabolites in human plasma
    Gor, Parul
    Alnouti, Yazen
    Reed, Gregory A.
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2011, 55 (05) : 1127 - 1135